$DCTH
Delcath Systems Inc

2024 Q3 Form 10-Q Financial Statement

#000162828024034769 Filed on August 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $11.20M $7.766M
YoY Change 2480.65% 1468.89%
Cost Of Revenue $1.640M $1.519M
YoY Change 1133.08% 912.67%
Gross Profit $9.560M $6.247M
YoY Change 3076.08% 1710.72%
Gross Profit Margin 85.36% 80.44%
Selling, General & Admin $6.953M $6.765M
YoY Change 12.24% 41.32%
% of Gross Profit 72.73% 108.29%
Research & Development $3.866M $3.394M
YoY Change -17.07% -4.53%
% of Gross Profit 40.44% 54.33%
Depreciation & Amortization $100.0K $100.0K
YoY Change 0.0% 0.0%
% of Gross Profit 1.05% 1.6%
Operating Expenses $10.82M $10.16M
YoY Change -0.35% 21.78%
Operating Profit -$1.259M -$3.912M
YoY Change -88.07% -51.08%
Interest Expense $113.0K -$84.00K
YoY Change -128.61% -77.36%
% of Operating Profit
Other Income/Expense, Net $35.00K $10.00K
YoY Change -800.0% 66.67%
Pretax Income -$13.74M
YoY Change 90.79%
Income Tax
% Of Pretax Income
Net Earnings $1.864M -$13.74M
YoY Change -109.16% 90.79%
Net Earnings / Revenue 16.64% -176.94%
Basic Earnings Per Share $0.06 -$0.48
Diluted Earnings Per Share $0.06 -$0.48
COMMON SHARES
Basic Shares Outstanding 28.00M shares 27.79M shares
Diluted Shares Outstanding 32.35M shares 28.36M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.99M $19.91M
YoY Change -65.42% 36.91%
Cash & Equivalents $8.315M $14.78M
Short-Term Investments $5.677M $5.124M
Other Short-Term Assets $1.428M
YoY Change -38.58%
Inventory $6.642M $6.316M
Prepaid Expenses
Receivables $6.936M $3.726M
Other Receivables $23.00K
Total Short-Term Assets $28.88M $31.40M
YoY Change -37.34% 61.25%
LONG-TERM ASSETS
Property, Plant & Equipment $1.729M $1.422M
YoY Change 25.84% 1.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.799M $2.514M
YoY Change 88.99% 59.32%
TOTAL ASSETS
Total Short-Term Assets $28.88M $31.40M
Total Long-Term Assets $2.799M $2.514M
Total Assets $31.68M $33.91M
YoY Change -33.41% 61.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $937.0K $3.279M
YoY Change 24.44% 239.44%
Accrued Expenses $5.706M $4.418M
YoY Change 9.1% -20.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $4.491M
YoY Change -0.42%
Total Short-Term Liabilities $21.58M $12.29M
YoY Change 54.46% 10.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $563.0K $632.0K
YoY Change -49.32% -44.85%
Total Long-Term Liabilities $563.0K $632.0K
YoY Change -49.32% -44.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.58M $12.29M
Total Long-Term Liabilities $563.0K $632.0K
Total Liabilities $23.11M $29.72M
YoY Change 1.1% 39.59%
SHAREHOLDERS EQUITY
Retained Earnings -$528.2M -$530.0M
YoY Change 6.91% 11.89%
Common Stock $280.0K $279.0K
YoY Change 42.13% 82.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.571M $4.192M
YoY Change
Total Liabilities & Shareholders Equity $31.68M $33.91M
YoY Change -33.41% 61.11%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $1.864M -$13.74M
YoY Change -109.16% 90.79%
Depreciation, Depletion And Amortization $100.0K $100.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$4.451M
YoY Change -53.87%
INVESTING ACTIVITIES
Capital Expenditures $101.0K
YoY Change 152.5%
Acquisitions
YoY Change
Other Investing Activities $10.39M
YoY Change
Cash From Investing Activities $10.28M
YoY Change -25810.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.854M
YoY Change -40871.43%
NET CHANGE
Cash From Operating Activities -4.451M
Cash From Investing Activities 10.28M
Cash From Financing Activities -2.854M
Net Change In Cash 2.979M
YoY Change -130.77%
FREE CASH FLOW
Cash From Operating Activities -$4.451M
Capital Expenditures $101.0K
Free Cash Flow -$4.552M
YoY Change -53.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
12342 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27931393 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22761554 shares
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-530014000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
4192000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33913000 usd
us-gaap Cost Of Revenue
CostOfRevenue
331000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
279000 usd
us-gaap Gross Profit
GrossProfit
761000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8131000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8952000 usd
us-gaap Operating Expenses
OperatingExpenses
17083000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16322000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1160000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1059000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16202000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24979000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28364731 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12463665 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.88
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12291000 usd
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
15809000 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27931393 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
228000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
520576000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-505162000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
135000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
15777000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38613000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
22836000 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
19000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16183000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26625955 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12035738 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Operating Expenses
OperatingExpenses
22673000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16448000 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5548000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
989000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
632000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
840000 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7766000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
495000 usd
CY2024Q2 us-gaap Revenues
Revenues
7766000 usd
CY2023Q2 us-gaap Revenues
Revenues
495000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
29721000 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
533919000 usd
dei City Area Code
CityAreaCode
212
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1091000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
37158000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1352000 usd
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
12342 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22761554 shares
us-gaap Revenues
Revenues
10905000 usd
us-gaap Revenues
Revenues
1092000 usd
us-gaap Cost Of Revenue
CostOfRevenue
2422000 usd
us-gaap Gross Profit
GrossProfit
8483000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7094000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15579000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14190000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10367000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-283000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 usd
us-gaap Net Income Loss
NetIncomeLoss
-24852000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-133000 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28364731 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12035738 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5859000 usd
CY2023Q1 dcth Issuance Of Common Stock In Private Placement
IssuanceOfCommonStockInPrivatePlacement
56000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
47000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
19000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-13076000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-242000 usd
us-gaap Net Income Loss
NetIncomeLoss
-24852000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16202000 usd
dcth Stock Option Compensation Income Expense
StockOptionCompensationIncomeExpense
6014000 usd
dcth Stock Option Compensation Income Expense
StockOptionCompensationIncomeExpense
3322000 usd
us-gaap Depreciation
Depreciation
62000 usd
us-gaap Depreciation
Depreciation
59000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10367000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1160000 usd
dcth Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
37000 usd
dcth Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
195000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
447000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
388000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
80000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
80000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
379000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
488000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
306000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3485000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-239000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2994000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
482000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1339000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
132000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-183000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-177000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14035000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13912000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
20482000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
35540000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
114000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14944000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6771000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
22960000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
6107000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
6313000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
259000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
169000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1167000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16701000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2086000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2768000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12696000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11822000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14782000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14590000 usd
CY2024Q2 us-gaap Cash
Cash
14782000 usd
CY2023Q2 us-gaap Cash
Cash
14540000 usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14782000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14590000 usd
us-gaap Interest Paid Net
InterestPaidNet
375000 usd
us-gaap Interest Paid Net
InterestPaidNet
787000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1029000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
84000 usd
dcth Conversion Of Temporary Equity To Common Shares
ConversionOfTemporaryEquityToCommonShares
0 usd
dcth Conversion Of Temporary Equity To Common Shares
ConversionOfTemporaryEquityToCommonShares
11269000 usd
dcth Conversion Of Temporary Equity To Preferred Shares
ConversionOfTemporaryEquityToPreferredShares
0 usd
dcth Conversion Of Temporary Equity To Preferred Shares
ConversionOfTemporaryEquityToPreferredShares
7099000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14800000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5100000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12700000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
19800000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14000000.0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
6100000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7766000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
495000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10905000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1092000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5124000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
19808000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
200000 usd
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
3590000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1443000 usd
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
2162000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1753000 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
564000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
126000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
6316000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
3322000 usd
CY2024Q2 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
222000 usd
CY2023Q4 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
222000 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
145000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
157000 usd
CY2024Q2 dcth Prepaid Professional Services Current
PrepaidProfessionalServicesCurrent
657000 usd
CY2023Q4 dcth Prepaid Professional Services Current
PrepaidProfessionalServicesCurrent
133000 usd
CY2024Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
23000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
151000 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
404000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
428000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1451000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1091000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6545000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6427000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5123000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5075000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1422000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1352000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
100000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
100000 usd
CY2024Q2 dcth Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
419000 usd
CY2023Q4 dcth Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1129000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2302000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1859000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
165000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
272000 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
793000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
713000 usd
CY2024Q2 dcth Accrued Inventory Current
AccruedInventoryCurrent
8000 usd
CY2023Q4 dcth Accrued Inventory Current
AccruedInventoryCurrent
585000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
731000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
691000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4418000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5249000 usd
CY2024Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
37000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
61000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
93000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
187000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
169000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
148000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
153000 usd
CY2024Q2 dcth Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
800000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1550000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
458000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1092000 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4503000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
12000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
4491000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10610000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
460000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10150000 usd
dcth Percentage Of Final Payment Included In Gross Amount
PercentageOfFinalPaymentIncludedInGrossAmount
0.0425
dcth Debt Instrument Final Payment
DebtInstrumentFinalPayment
500000 usd
CY2021Q3 dcth Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
127755 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
34072 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
10000000 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
10000000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 dcth Preferred Stock Shares Designated
PreferredStockSharesDesignated
179670 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.143
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.616
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0422
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0394
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4183232 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.17
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
7.60
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
147000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2213096 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.09
dcth Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P9Y6M
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
32300 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.22
dcth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
4.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
60000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
46956 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.63
dcth Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
8.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
184958 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
5.49
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6132114 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.11
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
6.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12902000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2995121 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.95
CY2024Q2 dcth Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageGrantDateFairValue
8.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3443000 usd
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3136993 shares
CY2024Q2 dcth Share Based Compensation Arrangement By Share Based Payment Award Option Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionUnvestedWeightedAverageExercisePrice
5.36
CY2024Q2 dcth Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageGrantDateFairValue
4.73
dcth Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y3M18D
CY2024Q2 dcth Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue
9459000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6132114 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6132114 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3069000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1661000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6014000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3322000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8300000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D
CY2021Q3 dcth Share Based Compensation Arrangement By Share Based Payment Award Stock Plan Offering Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod
P6M
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15768923 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24222787 shares
CY2024Q2 dcth Number Of Shares Pre Funded Penny Warrants Outstanding
NumberOfSharesPreFundedPennyWarrantsOutstanding
737421 shares
CY2023Q2 dcth Number Of Shares Pre Funded Penny Warrants Outstanding
NumberOfSharesPreFundedPennyWarrantsOutstanding
1037792 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
27317256 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
11320450 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
25511315 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
10693762 shares
CY2024Q2 dcth Weighted Average Number Of Shares Pre Funded Warrants
WeightedAverageNumberOfSharesPreFundedWarrants
1047475 shares
CY2023Q2 dcth Weighted Average Number Of Shares Pre Funded Warrants
WeightedAverageNumberOfSharesPreFundedWarrants
1143215 shares
dcth Weighted Average Number Of Shares Pre Funded Warrants
WeightedAverageNumberOfSharesPreFundedWarrants
1114640 shares
dcth Weighted Average Number Of Shares Pre Funded Warrants
WeightedAverageNumberOfSharesPreFundedWarrants
1341976 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28364731 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28364731 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12463665 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12463665 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26625955 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26625955 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12035738 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12035738 shares
CY2021Q4 dcth Milestone Payment Unpaid
MilestonePaymentUnpaid
1000000 eur
CY2024Q2 dcth Supply Agreement Renewal Option Term
SupplyAgreementRenewalOptionTerm
P5Y
CY2024Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
2400000 usd
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
6544000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-25000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10367000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
106000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
221000 usd
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
16559000 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
9800000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10400000 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10590000 usd
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
750000 usd
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
15809000 usd
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
16559000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
20200000 usd
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
996000 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
5548000 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
6544000 usd

Files In Submission

Name View Source Status
0001628280-24-034769-index-headers.html Edgar Link pending
0001628280-24-034769-index.html Edgar Link pending
0001628280-24-034769.txt Edgar Link pending
0001628280-24-034769-xbrl.zip Edgar Link pending
dcth-20240630.htm Edgar Link pending
dcth-20240630.xsd Edgar Link pending
dcth-20240630xexx311.htm Edgar Link pending
dcth-20240630xexx312.htm Edgar Link pending
dcth-20240630xexx321.htm Edgar Link pending
dcth-20240630xexx322.htm Edgar Link pending
dcth-20240630_cal.xml Edgar Link unprocessable
dcth-20240630_def.xml Edgar Link unprocessable
dcth-20240630_htm.xml Edgar Link completed
delcath-lscmagreementxamen.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
dcth-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dcth-20240630_pre.xml Edgar Link unprocessable